NCT05238831 2024-01-23SMMART Adaptive Clinical Treatment (ACT) TrialOHSU Knight Cancer InstitutePhase EARLY_PHASE1 Withdrawn
NCT04464967 2021-05-12Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersNKGen Biotech, Inc.Phase 1/2 Withdrawn
NCT00004074 2013-02-28Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuNational Cancer Institute (NCI)Phase 1 Completed15 enrolled
NCT00005842 2013-02-11Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic CancerNational Cancer Institute (NCI)Phase 1 Completed24 enrolled
NCT00433407 2012-10-04T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid TumorsJonsson Comprehensive Cancer CenterPhase NA Completed12 enrolled